Exanta Committee Review Reflects "Regulatory" Vs. "Clinical" Medicine – AstraZeneca

AstraZeneca tells investors it cannot determine what its next step will be in the U.S. until it hears from FDA by the Oct. 23 user fee date. CEO McKillop says "we can't be optimistic about the outcome of discussions with the FDA."